The price of Coherus Biosciences Inc (NASDAQ: CHRS) closed at $2.28 in the last session, down -2.15% from day before closing price of $2.33. In other words, the price has decreased by -$0.0500 from its previous closing price. On the day, 1918792 shares were traded. CHRS stock price reached its highest trading level at $2.4000 during the session, while it also had its lowest trading level at $2.2600.
Ratios:
We take a closer look at CHRS’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 1.24 and its Current Ratio is at 1.43.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Robert W. Baird on November 17, 2023, initiated with a Outperform rating and assigned the stock a target price of $11.
On July 24, 2023, Citigroup started tracking the stock assigning a Buy rating and target price of $12.Citigroup initiated its Buy rating on July 24, 2023, with a $12 target price.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Nov 22 ’23 when Lanfear Dennis M sold 223,100 shares for $2.02 per share. The transaction valued at 449,770 led to the insider holds 731,693 shares of the business.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CHRS now has a Market Capitalization of 263.19M and an Enterprise Value of 626.28M. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.99. Its current Enterprise Value per Revenue stands at 2.43 whereas that against EBITDA is -3.23.
Stock Price History:
Over the past 52 weeks, CHRS has reached a high of $8.65, while it has fallen to a 52-week low of $1.43. The 50-Day Moving Average of the stock is 2.3970, while the 200-Day Moving Average is calculated to be 3.3899.
Shares Statistics:
According to the various share statistics, CHRS traded on average about 5.96M shares per day over the past 3-months and 3.2M shares per day over the past 10 days. A total of 112.22M shares are outstanding, with a floating share count of 106.17M. Insiders hold about 4.67% of the company’s shares, while institutions hold 76.48% stake in the company. Shares short for CHRS as of Feb 29, 2024 were 24.2M with a Short Ratio of 4.06, compared to 28.13M on Jan 31, 2024. Therefore, it implies a Short% of Shares Outstanding of 21.73% and a Short% of Float of 26.04%.
Earnings Estimates
The company has 4 analysts who recommend its stock at the moment. On average, analysts expect EPS of -$0.23 for the current quarter, with a high estimate of -$0.05 and a low estimate of -$0.37, while EPS last year was -$0.75. The consensus estimate for the next quarter is -$0.22, with high estimates of -$0.04 and low estimates of -$0.33.
Analysts are recommending an EPS of between -$0.41 and -$0.88 for the fiscal current year, implying an average EPS of -$0.72. EPS for the following year is $0.07, with 4 analysts recommending between $0.68 and -$0.57.
Revenue Estimates
According to 5 analysts, the current quarter’s revenue is expected to be $81.7M. It ranges from a high estimate of $102M to a low estimate of $47.07M. As of the current estimate, Coherus Biosciences Inc’s year-ago sales were $47.44M, an estimated increase of 72.20% from the year-ago figure.
A total of 6 analysts have provided revenue estimates for CHRS’s current fiscal year. The highest revenue estimate was $324M, while the lowest revenue estimate was $206.49M, resulting in an average revenue estimate of $261.92M. In the same quarter a year ago, actual revenue was $257.24M, up 1.80% from the average estimate. Based on 6 analysts’ estimates, the company’s revenue will be $357.3M in the next fiscal year. The high estimate is $513.75M and the low estimate is $279.91M. The average revenue growth estimate for next year is up 36.40% from the average revenue estimate for this year.
